Psoriasis

US claims data show patients with generalized pustular psoriasis (GPP) face up to a 4-fold higher mortality risk compared with the general population.

Ustekinumab offers superior itch relief for severe psoriasis compared with guselkumab, new data show.

Once-daily roflumilast provides skin clearance and rapid itch relief with no limitation on duration of use.

The impact of psoriasis on quality of life goes beyond clinical measures, such as psoriasis area severity index (PASI) and body surface area (BSA), a study finds.

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of once-daily icotrokinra (JNJ-2113) in adolescents with moderate to severe plaque psoriasis.

Biologics for psoriasis had lower drug survival in women compared with men, according to one study.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug survival of almost 3 years.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety and efficacy findings.

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving quality of life in patients with moderate to severe scalp psoriasis.

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to severe psoriasis across 2 studies.

Both drugs showed significant improvements, with higher response observed for bimekizumab, study finds.

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival challenges.

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), revealing higher hospitalizations and costs among patients experiencing flares.

These findings may offer more personalized treatment and prevention recommendations for patients with psoriasis.

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality of life for patients with psoriasis.

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

Psychological resilience plays an important role in managing psoriasis symptoms and enhancing patient well-being, study reveals.

Study highlights barriers to care, treatment preferences, and interest in research participation in psoriasis in the Latine community.

The most-read psoriasis content in 2024 covered efficacy and safety findings of various drug clinical trials.

Novel strategies in the VISIBLE trial set a new standard for recruiting and retaining diverse participants with skin of color in dermatology clinical trials.

Researchers found patients reporting greater disease burden and lower health-related quality of life (HRQoL) are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.